A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2018 Status changed from recruiting to completed.
- 21 Apr 2011 Planned end date (Jan 2014) added as reported by ClinicalTrials.gov.
- 02 Aug 2007 New trial record.